Bugworks and GARDP collaborate to accelerate development of novel antibiotic to treat serious infections

9 August 2023



8 August 2023

Biopharmaceutical company Bugworks Research, which has research and development facilities in Bengaluru, has entered a partnership with the Global Antibiotic Research and Development Partnership (GARDP) based out of Switzerland. The collaboration aims to accelerate the development of an antibiotic compound for treating serious infections caused by multidrug-resistant bacteria.

A clinical-stage biopharmaceutical company, Bugworks develops multi-target therapeutic assets in the anti-infectives and oncology areas. It is currently developing the compound BWC0977 which aims to address problems arising from serious hospital and community infections, and bacterial biothreats.

The compound will go through Phase-1 clinical trials next year. As part of the collaboration, GARDP would provide resources and funding for up to $20 million once the trials are a success.


Read the article